Bioengineered 2'-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines.
Human milk oligosaccharides help to prevent infectious diseases in breastfed infants. Larger scale testing, particularly in animal models and human clinical studies, is still limited due to shortened availability of more complex oligosaccharides. The purpose of this study was to evaluate 2'-fucosyllactose (2'-FL) and 3-fucosyllactose (3-FL) synthesized by whole-cell biocatalysis for their biological activity in vitro. Therefore, we have tested these oligosaccharides for their inhibitory potential of pathogen adhesion in two different human epithelial cell lines. 2'-FL could inhibit adhesion of Campylobacter jejuni, enteropathogenic Escherichia coli, Salmonella enterica serovar fyris, and Pseudomonas aeruginosa to the intestinal human cell line Caco-2 (reduction of 26%, 18%, 12%, and 17%, respectively), as could be shown for 3-FL (enteropathogenic E coli 29%, P aeruginosa 26%). Furthermore, adherence of P aeruginosa to the human respiratory epithelial cell line A549 was significantly inhibited by 2'-FL and 3-FL (reduction of 24% and 23%, respectively). These results confirm the biological and functional activity of biotechnologically synthesized human milk oligosaccharides. Mass-tailored human milk oligosaccharides could be used in the future to supplement infant formula ingredients or as preventatives to reduce the impact of infectious diseases.
Pediatric Infectious Diseases, University Children's Hospital Mannheim of Heidelberg University, Germany. Electronic address: Stefan.Weichert@medma.uni-heidelberg.de.
Stefan
S
Weichert
Stefan
S
Jennewein
Eric
E
Hüfner
Christel
C
Weiss
Julia
J
Borkowski
Johannes
J
Putze
Horst
H
Schroten
D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000187:drug effects*; D055162:Biocatalysis; D057005:Bioengineering; D001942:Breast Feeding; D018938:Caco-2 Cells; D016123:Campylobacter jejuni / Q000187:drug effects / Q000472:pathogenicity; D054308:Enteropathogenic Escherichia coli / Q000187:drug effects / Q000472:pathogenicity; D004847:Epithelial Cells / Q000187:drug effects / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D007239:Infections / Q000382:microbiology; D007422:Intestines / Q000187:drug effects* / Q000382:microbiology; D008895:Milk, Human / Q000737:chemistry*; D009844:Oligosaccharides / Q000096:biosynthesis / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity; D012137:Respiratory System / Q000187:drug effects* / Q000382:microbiology; D019779:Salmonella enterica / Q000187:drug effects / Q000472:pathogenicity; D014312:Trisaccharides / Q000096:biosynthesis / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D009844:Oligosaccharides; D014312:Trisaccharides; C035714:3'-fucosyllactose; C031420:2'-fucosyllactose
2′-FL; 2′-fucosyllactose; 3-FL; 3-fucosyllactose; 3′-fucosyllactose; Bacterial adhesion; CFU; Cell culture techniques; EPEC; Fuc; HMO; HPAEC-PAD; Human milk; LNFP; MOI; colony forming units; enteropathogenic Escherichia coli; high pH anion exchange chromatography with pulsed amperometric detection; human milk oligosaccharide; l-fucose; lacto-N-fucopentaose; multiplicity of infection.